Asset Details
Do you wish to reserve the book?
Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions
Do you wish to request the book?
Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions
2015
Overview
Telavancin (TD-6424) was discovered in 2000 and became the first marketed semisynthetic lipoglycopeptide in 2009. This parenteral antibacterial agent has a dual mechanism of action and potent in vitro activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and isolates with reduced vancomycin susceptibility. Pharmacokinetic and pharmacodynamic analyses support the concentration-dependent activity and once-daily dosing regimen of telavancin. A changing regulatory approval process, manufacturing obstacles, and the termination of a commercialization partnership have challenged the development and marketing of telavancin. The commercial operations for telavancin have been restored, a new manufacturer has been secured, and reliable product supplies are available for clinical use. In addition, telavancin continues to be supported by ongoing clinical research with the recent launch of the Telavancin Observational Use Registry (TOUR; NCT02288234) in the United States and an international phase 3, randomized trial comparing telavancin with standard therapy for the treatment of patients with complicated S. aureus bacteremia, including endocarditis (NCT02208063).
Publisher
Oxford University Press
Subject
Aminoglycosides - pharmacokinetics
/ Aminoglycosides - pharmacology
/ Aminoglycosides - therapeutic use
/ Animals
/ Anti-Bacterial Agents - pharmacology
/ Anti-Bacterial Agents - therapeutic use
/ Gram-Positive Bacterial Infections - drug therapy
/ Gram-Positive Bacterial Infections - microbiology
/ Humans
/ Methicillin-Resistant Staphylococcus aureus - drug effects
/ Peptides
/ United States Food and Drug Administration - legislation & jurisprudence
